Versiti Acquires Cenetron Central Laboratories and Salus IRB

July 24, 2019

Applied Clinical Trials

Versiti has announced the acquisition of Texas-based Cenetron Central Laboratories, and its subsidiary, Salus IRB. The acquisition will not impact Cenetron’s 40 employees, and the laboratory will maintain its name and current location in Austin.

For more details, click here. 

Related Content:

News